$340 Million is the total value of Ghost Tree Capital, LLC's 46 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $20,683,000 | – | 210,000 | +100.0% | 6.09% | – |
| BLUE | New | BLUEBIRD BIO INC | $16,480,000 | – | 105,000 | +100.0% | 4.85% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $10,938,000 | – | 242,000 | +100.0% | 3.22% | – |
| EXEL | New | EXELIXIS INC | $8,608,000 | – | 400,000 | +100.0% | 2.53% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $6,573,000 | – | 23,500 | +100.0% | 1.93% | – |
| AVRO | New | AVROBIO INC | $6,569,000 | – | 230,000 | +100.0% | 1.93% | – |
| TCDA | New | TRICIDA INC | $5,562,000 | – | 186,019 | +100.0% | 1.64% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $4,776,000 | – | 125,000 | +100.0% | 1.41% | – |
| KURA | New | KURA ONCOLOGY INC | $4,186,000 | – | 230,000 | +100.0% | 1.23% | – |
| BDSI | New | BIODELIVERY SCIENCES INTL IN | $4,163,000 | – | 1,411,247 | +100.0% | 1.22% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $4,070,000 | – | 185,000 | +100.0% | 1.20% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $3,016,000 | – | 3,525,000 | +100.0% | 0.89% | – |
| ZFGN | New | ZAFGEN INC | $1,046,000 | – | 102,263 | +100.0% | 0.31% | – |
| ACOR | New | ACORDA THERAPEUTICS INC | $947,000 | – | 33,000 | +100.0% | 0.28% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $828,000 | – | 14,000 | +100.0% | 0.24% | – |
| EDGE | New | EDGE THERAPEUTICS INC | $773,000 | – | 750,792 | +100.0% | 0.23% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $608,000 | – | 29,000 | +100.0% | 0.18% | – |
| LCI | New | LANNET INCcall | $520,000 | – | 2,000 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
| 13F-HR | 2021-11-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.